Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751).
무작위 임상시험
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
154 patients with lymphoma admitted to The First Hospital of Jilin University from September 2020 to September 2022 was conducted.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] PEG-rhG-CSF was more effective than G-CSF in preventing neutropenia induced by chemotherapy regimens with a moderate- to-high-risk of FN in patients with lymphoma and contributes to better chemotherapy efficacy. [TRIAL REGISTRATION] ClinicalTrials.gov NCT05834751.
[BACKGROUND] Neutropenia is one of the most common complications of chemotherapy in lymphoma patients.
- p-value P=0.059
- p-value P=0.02
APA
Wang B, Cao L, et al. (2025). Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751).. Translational cancer research, 14(12), 8990-9001. https://doi.org/10.21037/tcr-2025-1-2613
MLA
Wang B, et al.. "Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751).." Translational cancer research, vol. 14, no. 12, 2025, pp. 8990-9001.
PMID
41510127 ↗
Abstract 한글 요약
[BACKGROUND] Neutropenia is one of the most common complications of chemotherapy in lymphoma patients. To treat and prevent this condition, polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; mecapegfilgrastim) has been developed. This study compared the efficacy of PEG-rhG-CSF with that of recombinant human granulocyte colony-stimulating factor (G-CSF) in preventing neutropenia after chemotherapy for lymphoma.
[METHODS] A prospective randomized study of 154 patients with lymphoma admitted to The First Hospital of Jilin University from September 2020 to September 2022 was conducted. The predetermined sample size is established with a power analysis-driven approach, followed by rigorous non-inferiority testing to evaluate therapeutic equivalence. The patients were randomized at a 1:1 ratio to receive PEG-rhG-CSF or G-CSF. The duration and incidence of grade 3 or higher neutropenia (≥ G3 neutropenia), and the occurrence rates of febrile neutropenia (FN) and ≥ G3 neutropenia were compared between the two groups. A subgroup analysis was performed based on the chemotherapy regimen and tumor origin.
[RESULTS] The duration of ≥ G3 neutropenia in the first cycle of chemotherapy was 1.56±2.23 days in the PEG-rhG-CSF group and 2.34±2.82 days in the G-CSF group (P=0.059). The incidence of ≥ G3 neutropenia in the first cycle of chemotherapy was 44.16% in the PEG-rhG-CSF group and 53.25% in the G-CSF group (P=0.26). The incidence of ≥ G3 neutropenia in cycles 2-4 of chemotherapy was 22.08% in the PEG-rhG-CSF group and 38.96% in the G-CSF group (P=0.02). After four cycles, the complete response rate of the PEG-rhG-CSF group was 73.58%, while that of the G-CSF group was 63.64%.
[CONCLUSIONS] PEG-rhG-CSF was more effective than G-CSF in preventing neutropenia induced by chemotherapy regimens with a moderate- to-high-risk of FN in patients with lymphoma and contributes to better chemotherapy efficacy.
[TRIAL REGISTRATION] ClinicalTrials.gov NCT05834751.
[METHODS] A prospective randomized study of 154 patients with lymphoma admitted to The First Hospital of Jilin University from September 2020 to September 2022 was conducted. The predetermined sample size is established with a power analysis-driven approach, followed by rigorous non-inferiority testing to evaluate therapeutic equivalence. The patients were randomized at a 1:1 ratio to receive PEG-rhG-CSF or G-CSF. The duration and incidence of grade 3 or higher neutropenia (≥ G3 neutropenia), and the occurrence rates of febrile neutropenia (FN) and ≥ G3 neutropenia were compared between the two groups. A subgroup analysis was performed based on the chemotherapy regimen and tumor origin.
[RESULTS] The duration of ≥ G3 neutropenia in the first cycle of chemotherapy was 1.56±2.23 days in the PEG-rhG-CSF group and 2.34±2.82 days in the G-CSF group (P=0.059). The incidence of ≥ G3 neutropenia in the first cycle of chemotherapy was 44.16% in the PEG-rhG-CSF group and 53.25% in the G-CSF group (P=0.26). The incidence of ≥ G3 neutropenia in cycles 2-4 of chemotherapy was 22.08% in the PEG-rhG-CSF group and 38.96% in the G-CSF group (P=0.02). After four cycles, the complete response rate of the PEG-rhG-CSF group was 73.58%, while that of the G-CSF group was 63.64%.
[CONCLUSIONS] PEG-rhG-CSF was more effective than G-CSF in preventing neutropenia induced by chemotherapy regimens with a moderate- to-high-risk of FN in patients with lymphoma and contributes to better chemotherapy efficacy.
[TRIAL REGISTRATION] ClinicalTrials.gov NCT05834751.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of botulinum neurotoxin in the treatment of hemifacial spasms: a systematic review and meta-analysis.
- Updated evaluation of additional surgery versus non-gastrectomy treatment for early gastric cancer after noncurative endoscopic resection: a meta-analysis.
- The role of PCMT1 in prognosis tumor immune microenvironment and therapeutic responses across cancers.
- Optimization of strain-correlated electronic modulation and interfacial microenvironment for oxide-shielded PdGa nanosheets toward bifunctional electrocatalysis.
- TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Acquired L858R mutation following -TKI resistance in lung adenocarcinoma: a case report.
- Counting the Cost: Anticipated Financial Burden and Post-Traumatic Stress Symptoms in Patients Newly Diagnosed with Leukemia and Lymphoma.
- Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience.
- Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
- Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.